Core Viewpoint - BillionToOne, Inc. has appointed Anthony Pagano to its Board of Directors, effective January 1, 2026, enhancing its leadership team as it aims for growth in the molecular diagnostics sector [1][5]. Company Overview - BillionToOne is a next-generation molecular diagnostics company headquartered in Menlo Park, California, focused on creating powerful and accurate tests that are accessible to all [6]. - The company utilizes a patented technology called Quantitative Counting Templates™ (QCT™), which is the only multiplex technology capable of accurately counting DNA molecules at the single-molecule level [6]. Leadership Appointment - Anthony Pagano, currently the Chief Financial Officer and Executive Vice President of Genmab, will also serve as Chair of the Audit Committee at BillionToOne [1][2]. - Pagano has a strong track record in financial performance and strategic growth, having contributed to Genmab's revenue growth from $100 million to over $3 billion during his tenure [2]. - His previous experience includes roles at NovaDel Pharma and KPMG LLP, where he provided audit and mergers & acquisitions consulting services [3][4]. Strategic Importance - Pagano's appointment is seen as a significant enhancement to BillionToOne's Board, with expectations that his financial expertise and leadership in high-growth life sciences will be crucial for the company's mission [5].
BillionToOne Appoints Anthony Pagano to Board of Directors as Audit Committee Chair